influenza virus vaccine, monovalent a/h3n2v a/minnesota/11/2010 nymc x-203

Vaccineexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jun 11, 2014 (NCT02100436)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • influenza virus vaccine, monovalent a/h3n2v a/minnesota/11/2010 nymc x-203

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02921997Phase 2Nov 7, 2016National Institute of Allergy and Infectious Diseases (NIAID)
NCT02100436Phase 2Jun 11, 2014National Institute of Allergy and Infectious Diseases (NIAID)
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government2212014
1 organizations
Page 1 / 1